185447-96-5Relevant articles and documents
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
-
, (2008/06/13)
The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.
Unsaturated 1-Amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
-
, (2008/06/13)
Unsaturated 1-Amino-alkylcyclohexane compounds which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.
Magnesium trifluoromethanesulfonimide(triflimide) promoted substitution reactions of allylic and benzylic acetates. Magnesium triflimide as a substitute for magnesium perchlorate.
Grieco, Paul A.,Handy, Scott T.
, p. 2645 - 2648 (2007/10/03)
Magnesium triflimide(10 mol% in methylene chloride) is a convenient catalyst for the nucleophilic substitution of allylic and benzylic acetates, and constitutes a useful alternative to magnesium perchlorate.